End-of-day quote
Shenzhen S.E.
06:00:00 2024-04-29 pm EDT
|
5-day change
|
1st Jan Change
|
82.65
CNY
|
-1.82%
|
|
+2.05%
|
-28.81%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
29,964
|
72,546
|
111,228
|
52,704
|
41,387
|
28,878
|
-
|
-
|
Enterprise Value (EV)
1 |
29,964
|
72,546
|
105,428
|
47,553
|
34,424
|
22,585
|
20,787
|
19,705
|
P/E ratio
|
54
x
|
97.1
x
|
99.1
x
|
16.4
x
|
18.5
x
|
24.9
x
|
17.5
x
|
15.1
x
|
Yield
|
0.39%
|
0.2%
|
0.18%
|
1.22%
|
1.55%
|
0.83%
|
1.02%
|
1.21%
|
Capitalization / Revenue
|
12.2
x
|
23
x
|
24
x
|
5.15
x
|
5.32
x
|
4.48
x
|
3.74
x
|
3.05
x
|
EV / Revenue
|
12.2
x
|
23
x
|
22.8
x
|
4.65
x
|
4.42
x
|
3.5
x
|
2.69
x
|
2.08
x
|
EV / EBITDA
|
40
x
|
74.3
x
|
83.1
x
|
13.6
x
|
9.5
x
|
13.7
x
|
9.58
x
|
7.41
x
|
EV / FCF
|
-
|
-163
x
|
-68.2
x
|
41.8
x
|
14.7
x
|
-327
x
|
26
x
|
20
x
|
FCF Yield
|
-
|
-0.61%
|
-1.47%
|
2.39%
|
6.82%
|
-0.31%
|
3.85%
|
5.01%
|
Price to Book
|
9.84
x
|
12.1
x
|
9.07
x
|
3.5
x
|
2.46
x
|
1.69
x
|
1.57
x
|
1.42
x
|
Nbr of stocks (in thousands)
|
323,935
|
339,521
|
368,307
|
364,755
|
364,426
|
357,344
|
-
|
-
|
Reference price
2 |
92.50
|
213.7
|
310.7
|
148.0
|
116.1
|
82.65
|
82.65
|
82.65
|
Announcement Date
|
2/28/20
|
4/15/21
|
3/30/22
|
3/30/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
2,460
|
3,150
|
4,632
|
10,230
|
7,781
|
6,447
|
7,729
|
9,454
|
EBITDA
1 |
748.6
|
976.8
|
1,269
|
3,498
|
3,623
|
1,645
|
2,169
|
2,659
|
EBIT
1 |
623.7
|
816.9
|
1,068
|
3,136
|
2,236
|
1,277
|
1,735
|
2,170
|
Operating Margin
|
25.35%
|
25.94%
|
23.05%
|
30.65%
|
28.73%
|
19.81%
|
22.45%
|
22.95%
|
Earnings before Tax (EBT)
1 |
623.6
|
814.4
|
1,193
|
3,725
|
2,557
|
1,400
|
1,835
|
2,290
|
Net income
1 |
553.9
|
722.1
|
1,069
|
3,302
|
2,269
|
1,247
|
1,728
|
2,020
|
Net margin
|
22.51%
|
22.93%
|
23.08%
|
32.27%
|
29.16%
|
19.34%
|
22.35%
|
21.37%
|
EPS
2 |
1.714
|
2.200
|
3.136
|
9.000
|
6.260
|
3.326
|
4.725
|
5.465
|
Free Cash Flow
1 |
-
|
-445.6
|
-1,547
|
1,136
|
2,347
|
-69
|
799.2
|
986.5
|
FCF margin
|
-
|
-14.15%
|
-33.39%
|
11.11%
|
30.16%
|
-1.07%
|
10.34%
|
10.43%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
32.49%
|
64.79%
|
-
|
36.85%
|
37.1%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
34.42%
|
103.45%
|
-
|
46.26%
|
48.83%
|
Dividend per Share
2 |
0.3571
|
0.4286
|
0.5714
|
1.800
|
1.800
|
0.6854
|
0.8411
|
0.9995
|
Announcement Date
|
2/28/20
|
4/15/21
|
3/30/22
|
3/30/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 S2
|
2022 S1
|
2022 Q3
|
2022 S2
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2023 S2
|
2024 Q1
|
2024 Q2
|
2024 S1
|
2024 Q3
|
2024 Q4
|
2024 S2
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
2,879
|
5,034
|
2,770
|
5,198
|
2,249
|
2,350
|
4,596
|
1,762
|
1,437
|
3,186
|
1,400
|
1,451
|
2,815
|
1,595
|
1,845
|
3,441
|
2,203
|
2,324
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
710.6
|
1,699
|
-
|
1,464
|
-
|
952
|
1,670
|
559.8
|
-
|
565.4
|
-
|
266.1
|
447.5
|
212.8
|
275.3
|
488
|
-
|
-
|
Operating Margin
|
24.69%
|
33.74%
|
-
|
28.17%
|
-
|
40.52%
|
36.35%
|
31.78%
|
-
|
17.75%
|
-
|
18.33%
|
15.9%
|
13.34%
|
14.92%
|
14.18%
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
559.6
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
980.8
|
-
|
-
|
-
|
-
|
523.7
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
35.41%
|
-
|
-
|
-
|
-
|
29.73%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
-
|
-
|
1.720
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/30/22
|
8/25/22
|
10/27/22
|
3/30/23
|
4/28/23
|
8/29/23
|
8/29/23
|
10/30/23
|
3/28/24
|
3/28/24
|
4/25/24
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
5,800
|
5,151
|
6,963
|
6,293
|
8,092
|
9,173
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-446
|
-1,547
|
1,136
|
2,347
|
-69
|
799
|
986
|
ROE (net income / shareholders' equity)
|
19.9%
|
18.2%
|
12.1%
|
23.4%
|
13.9%
|
6.76%
|
8.65%
|
9.51%
|
ROA (Net income/ Total Assets)
|
16%
|
13.2%
|
10.1%
|
19.8%
|
12.1%
|
5.96%
|
7.17%
|
8.12%
|
Assets
1 |
3,472
|
5,458
|
10,635
|
16,698
|
18,729
|
20,930
|
24,096
|
24,894
|
Book Value Per Share
2 |
9.400
|
17.70
|
34.20
|
42.30
|
47.30
|
48.90
|
52.60
|
58.30
|
Cash Flow per Share
2 |
1.850
|
1.680
|
3.310
|
8.960
|
9.600
|
4.780
|
4.450
|
5.470
|
Capex
1 |
511
|
1,015
|
1,660
|
2,151
|
1,203
|
1,209
|
1,278
|
1,363
|
Capex / Sales
|
20.76%
|
32.22%
|
35.83%
|
21.02%
|
15.46%
|
18.75%
|
16.54%
|
14.42%
|
Announcement Date
|
2/28/20
|
4/15/21
|
3/30/22
|
3/30/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
82.65
CNY Average target price
99.42
CNY Spread / Average Target +20.30% Consensus |
1st Jan change
|
Capi.
|
---|
| -28.81% | 3.99B | | +26.08% | 662B | | +21.85% | 546B | | -4.77% | 359B | | +16.97% | 323B | | +5.69% | 290B | | +13.68% | 234B | | +3.65% | 198B | | -11.12% | 194B | | -3.40% | 157B |
Other Pharmaceuticals
|